Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2026 | Combining isatuximab, lenalidomide, oral cyclophosphamide, & dexamethasone for HR smoldering myeloma

Maher Salamoon • 9 Sep 2026
SOHO 2026
General Cyclophosphamide Dexamethasone Isatuximab Lenalidomide

Maher Salamoon, MD, Al-Baironi Hospital, Damascus, Syria, discusses treating high-risk smoldering multiple myeloma, emphasizing the importance of early diagnosis and treatment to improve progression-free survival. Dr Salamoon presents a study in which a combination of isatuximab, lenalidomide, oral cyclophosphamide, and dexamethasone achieved a high overall response rate and progression-free survival, with manageable side effects. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Maher Salamoon

Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin
4:17
Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin
Maher Salamoon • 9 Sep 2026
Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents
5:31
Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents
Maher Salamoon • 8 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Combining chemotherapy, brentuximab vedotin, and nivolumab in advanced-stage Hodgkin's lymphoma
2:23
Combining chemotherapy, brentuximab vedotin, and nivolumab in advanced-stage Hodgkin's lymphoma
Maher Salamoon • 14 Jun 2025

Related Videos

Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin
4:17
Treating peripheral T-cell lymphoma with chemotherapy, avelumab and brentuximab vedotin
Maher Salamoon • 9 Sep 2026
Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents
5:31
Insights into the risk of pulmonary infections in patients with CLL treated with targeted agents
Maher Salamoon • 8 Sep 2026
Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals